Pyxis Oncology, Inc.
PYXSNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $13.9M | $16.1M | — | — | — | — |
| Operating income | −$84.4M | −$89.5M | −$82.2M | −$123.5M | −$69.7M | −$12.9M |
| Net income | −$79.6M | −$77.3M | −$73.8M | −$120.7M | −$76.0M | −$12.8M |
| Total assets | $91.5M | $157.2M | $173.7M | $211.4M | $280.0M | $10.2M |
| Total liabilities | $38.1M | $36.4M | $48.0M | $50.6M | $18.7M | $3.9M |
| Equity | $53.4M | $120.8M | $125.7M | $160.8M | $261.3M | −$15.6M |
| EPS (diluted) | $-1.28 | $-1.32 | $-1.85 | $-3.65 | $-8.95 | — |
| Shares out. | 61.6M | 58.1M | 37.0M | 32.8M | 32.2M | 1.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −609.2%
- Net margin
- −574.5%
- Return on equity
- −149.1%
- Return on assets
- −87.0%
- Return on capital (ROCE)
- −119.9%
- Liabilities / assets
- 41.6%
- Debt / equity
- 0.71×
- Book value / share
- $0.87
- Revenue growth (YoY)
- −14.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -16.86distress
- Accruals / assets
- −17.6%clean
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2026-05Study of PYX-106 in Solid Tumors
- Phase 1Recruitingreadout ~2026-07A Study of PYX-201 in Advanced Solid Tumors
- Phase 1/2Recruitingreadout ~2027-12-06Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Laurion Capital Management LpPassive (13G)Feb 9, 2026
- Millennium Management LlcPassive (13G)Oct 14, 2025
- Gordonmd Global Investments LpPassive (13G)Sep 23, 2025
- Blackrock, Inc.Passive (13G)Jul 17, 2025
- Integrated Core Strategies (Us) LlcPassive (13G)May 6, 2025
- Sullivan LaraActivist (13D)Apr 2, 2025
- Deep Track Capital, LpPassive (13G)Feb 14, 2025
- Ridgeback Capital Investments L.P.Passive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Humphrey RachelDirector | Apr 14, 2025 | Sell | 1,400 | $0.97 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.8M | 2.1 | -8.9% |
| Apr 30, 2026 | 2.0M | 5.5 | -12.5% |
| Apr 15, 2026 | 2.3M | 5.6 | -14.7% |
| Mar 31, 2026 | 2.7M | 7.4 | +6.8% |
| Mar 13, 2026 | 2.5M | 7.7 | -1.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 14, 2026
- Results of operations · Regulation FD disclosureMar 23, 2026
- Regulation FD disclosure · Other material eventDec 18, 2025
- Results of operationsNov 3, 2025
- Results of operationsAug 14, 2025
- Other material eventAug 4, 2025
- Director / officer changeJul 3, 2025
- Shareholder voteJun 18, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.